Over the past few months, ADMA Biologics (ADMA) has been able to record several key accomplishments and milestones. During the second quarter, the company received FDA approval for both BIVIGAM and ASCENIV. In addition, the company now has product licenses for Nabi-HB and BIVIGAM. What is more, ADMA has executed an equity financing of about $52M which will support the launches of BIVIGAM and ASCENIV. The company also reported encouraging Q2 earnings with big beats on EPS and revenue. Recently, ADMA announced the relaunch of BIVIGAM after a long and arduous PAS review